Thank you for the prompt upload as usual, it's much...

First 13 Last

Share
Profile

Follow
Session

1,478 Posts.

832

09/05/24

17:22

Post #: 73747884
Share

Originally posted by Medicine Man: ↑

Video of "PYC Investor Update Q2 2024 on 09 May 2024"

The highlight of this Investor call are as follows:

PYC has entered the transactional window – creating optionality with respect to access to capital. Stifel Biopharma reported on 29 Apr 2024 that “Mid-clinical-stage M&A leading the pack - We are seeing much more M&A this year in Phase 1 and Phase 2 than before. There are fewer platform and Phase 3 deals happening and fewer deals happening at the approved stage”.

RP11 drug represents an attractive commercial opportunity for PYC. According to Endpoints News, “The market opportunity is significant, despite CIDP’s low prevalence in the US of less than one in 100,000 people. Vyvgart Hytrulo could reach up to $1.5 billion in global peak sales by 2030 for CIDP alone, TD Cowen analyst Yaron Werber wrote, using the current $225,000 price tag in his calculations”.

PYC has refined the inclusion criteria for the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies. The Company is focusing on early-stage patients and visual fields to prioritise patients who are likely to demonstrate the most rapid response to VP-001 for treating RP11 in the lead up to the design and execution of the registrational trial. This doesn't mean that the drug would not work for late-stage patients, just their deterioration is slow and it might take months for efficacy to show, On the other hand, younger patients have more rapid deterioration and the RP11 drug could bring noticeable visual acuity in a short space of 4-8 weeks as reported by a patient who does a lot of screen work.

The Presentation Slides Pack is available at https://app.sharelinktechnologies.com/announcement/asx/2bb4042b1647f8658d7c3508f3a3a7d5

If you appreciate my effort, please hit the Like button in Youtube and the Good Analysis buttons below

Expand

Thank you for the prompt upload as usual, it's much appreciated.

PYC Price at posting: 9.6¢ Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

There are more pages in this discussion • 11 more messages in this thread...

First 13 Last

Add PYC (ASX) to my watchlist

(20min delay)
Last 12.0¢		Change -0.005(4.00%)		Mkt cap ! $559.9M

Open	High	Low	Value	Volume
12.5¢	13.3¢	12.0¢	$624.5K	5.016M

Buyers (Bids)

No.	Vol.	Price($)
15	1227634	12.0¢

Sellers (Offers)

Price($)	Vol.	No.
12.5¢	130000	2

View Market Depth

No.	Vol.	Price($)
15	1227634	0.120
13	1531061	0.115
11	503370	0.110
11	1225445	0.105
23	1558294	0.100

Price($)	Vol.	No.
0.125	130000	2
0.130	429500	3
0.135	547949	8
0.140	1503540	5
0.145	255000	2

Last trade - 16.10pm 09/07/2024 (20 minute delay)

PYC (ASX) Chart

Thank you for the prompt upload as usual, it's much...

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thank you for the prompt upload as usual, it&apos;s much...

Top Stories

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thank you for the prompt upload as usual, it's much...